

BRD3-Tndm (His) (Bromodomain containing protein 3 (RING3L), Tandem Brd's 1 & 2)

CATALOG NO.: RD-11-165

LOT NO.:


DESCRIPTION: Human recombinant BRD3, tandem construct comprising bromodomains 1 and 2 (residues 1-434; Genbank Accession # NM_007371; MW = 50.0 kDa) expressed in *E. coli* with an N-terminal His-tag. BRD3, like other human members of the BET family of chromatin-binding proteins (BRD2, BRD4, BRDT), comprises two bromodomains (see reviews^{1,2}), protein modules that bind ϵ -N-acetyllysine residues^{3,4}. Recent results suggest an important role for BRD3 in linking acetylation of both histones and non-histone proteins to gene transcription. When overexpressed in 293 cells, BRD3, along with BRD2, binds the hyperacetylated chromatin of transcribed genes, regions enriched in acetylated histone H4 lysine-5 (H4K5Ac), H4K12Ac, H3K14Ac, but deficient in H4K16Ac and H3K9me⁵. In an *in vitro* RNA polymerase II transcription system, binding of either BRD3 or BRD2 to a chromatin template assembled with hyperacetylated histones enabled transcription through the nucleosomes⁵. In addition to acetylated histones, BRD3-1 has been found to bind the hematopoietic transcription factor GATA1 and to enhance its chromatin binding and activation of target genes⁶. Like the binding of the bromodomains-1 of BRDT and BRD4 to H4K5Ac/K8Ac, interaction of BRD3-1 with GATA1 occurs via the simultaneous binding of K312Ac and K315Ac⁷. The BET family inhibitor, I-BET151, has shown efficacy in mouse models of MLL-fusion leukemias, displacing BRD3 and BRD4 from chromatin and inhibiting transcription of genes, e.g. *BCL2*, upregulated by the MLL-fusions⁸.

PURITY: >90% by SDS-PAGE


SUPPLIED AS: _ μ g/ μ L in 50 mM Tris/HCl, pH 7.5, 150 mM NaCl, 1.0 mM TCEP, 10% glycerol (v/v) as determined by OD₂₈₀

STORAGE: -70°C. Thaw quickly and store on ice before use. The remaining, unused, undiluted protein should be snap frozen, for example in a dry/ice ethanol bath or liquid nitrogen. Minimize freeze/thaws if possible, but very low volume aliquots (<5 μ l) or storage of diluted enzyme is not recommended.

REFERENCES: 1) B. Florence & D.V. Faller *Front. Biosci.* 2001 **6** D1008; 2) S.-Y. Wu & C.-M. Chiang *J. Biol. Chem.* 2007 **282** 13141; 3) D.J. Owen *et al. EMBO J.* 2000 **19** 6141; 4) L. Zeng & M.-M. Zhou *FEBS Lett.* 2002 **513** 124; 5) G. LeRoy *et al. Mol. Cell* 2008 **30** 51; 6) J.M. Lamonica *et al. Proc. Natl. Acad. Sci. USA* 2011 **108** E159; 7) R. Gamsjaeger *et al. Mol. Cell. Biol.* 2011 **31** 2632; 8) M.A. Dawson *et al. Nature* 2011 **478** 529



Coomassie blue stained SDS-PAGE (4-12% acrylamide) of 4 μ g of RBC BRD3-Tndm (His). MW markers (left lane) are, from top, 220, 160, 120, 100, 90, 80, 70, 60, 50, 40, 30, 25, 20, 15, 10 kDa.



Differential Scanning Fluorimetry of RBC BRD3-Tndm (His) in Presence or Absence of (+)JQ1. Thermal denaturation of BRD3-Tndm (His) is detected (CFX384™ Touch thermal cycler, 'FRET' channel; Bio-Rad) by increased binding and fluorescence of the dye SYPRO® Orange (Life Technologies). Addition of the BET bromodomain inhibitor/ligand (+)JQ1 (10 μ M) stabilizes the protein folding and shifts the T_m (inflection point) from 52°C to 59°C.

This product is not intended for therapeutic or diagnostic use in animals or in humans.

Reaction Biology

1 Great Valley Parkway, Malvern PA, USA 19355

requests@reactionbiology.com www.reactionbiology.com